Abstract:Abstract Background: The role of tetraspanins, particularly CD81 and CD82, in T cell activation, shedding light on their contribution to anti-tumor effects in the tumor microenvironment. The findings provide insights for potential applications of these tetraspanins in immunotherapy. Method: The study employed 10x Genomics for single-cell RNA sequencing and processed the data using Seurat. It focused on the tumor microenvironment, categorizing cell types, especially TIL subsets. T cells were sorted based on CD81 and CD82 expression and activated, and their activation markers and cytokine production were analyzed. Bulk RNA sequencing was performed on both sorted T cells and tumor samples, and the TCR repertoire was examined. Cytotoxicity of CD81 and CD82 transduced cells was measured using the xCELLigence RTCA HT system. Result: Tetraspanins have been linked to T cell co-stimulation and activation, with CD81 and CD82 playing a significant role in TCR signaling and activation. Single-cell and bulk RNA sequencing data from lung cancer patients reveal high expression of CD81 and CD82 in the tumor microenvironment, especially in T cells, correlating with T cell activation and cytokine production. In vitro experiments confirm the activation and effector cytokines, especially IFN-γ, TNF-α, and IL-2, producing potential of T cells expressing CD81 and CD82, suggesting their importance in anti-cancer immunity. Overexpression of CD81 and CD82 enhances T cell cytotoxicity against cancer cells, further supporting their role in T cell function. Despite some limitations, these findings shed light on the significant impact of tetraspanins in modulating immune responses, particularly in the context of cancer immunotherapy. Conclusion: We report that CD81 and CD82 serve as specific markers for activated T cells within the TME. CD81 and CD82 are correlated with the activation and regulation of T cells, and they may also mediate the regulation of relevant cytokines. Overall, our findings provide better insights into the molecular mechanisms regulating TILs present in the TME of non-small cell carcinoma and propose CD81 and CD82 as associated markers. These discoveries could serve as a foundation for the development of new immunotherapies targeting the TME. Citation Format: Kwangmin Na, Seul Lee, Dong Kwon Kim, Young Seob Kim, Joon Yeon Hwang, Seong-san Kang, Sujeong Baek, Chai Young Lee, Seung Min Yang, Yu Jin Han, Mi hyun Kim, Heekyung Han, Youngtaek Kim, Jae Hwan Kim, Seunghyun Jeon, Youngseon Byeon, Jii Bum Lee, Sun Min Lim, Min Hee Hong, Kyoung-Ho Pyo, Byoung Chul Cho. CD81 and CD82 in tumor infiltrating lymphocytes within the NSCLC tumor microenvironment play a crucial role in T cell activation and cytokine production [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6805.

CD81 and CD82 expressing tumor-infiltrating lymphocytes in the NSCLC tumor microenvironment play a crucial role in T-cell activation and cytokine production

Abstract 6805: CD81 and CD82 in tumor infiltrating lymphocytes within the NSCLC tumor microenvironment play a crucial role in T cell activation and cytokine production

CD57+CD8+T Cells and Response to PD-1/PD-L1 Blockade in Patients with NSCLC

Peritumoral CD90+CD73+ cells possess immunosuppressive features in human non-small cell lung cancer

A subset of neutrophils activates anti-tumor immunity and inhibits non-small-cell lung cancer progression

Deciphering the tumor microenvironment cell–infiltrating landscape reveals microenvironment subtypes and therapeutic potentials for nonsquamous NSCLC

Spatial colocalization and combined survival benefit of natural killer and CD8 T cells despite profound MHC class I loss in non-small cell lung cancer

A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy

Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products

Functional status and spatial interaction of T cell subsets driven by specific tumor microenvironment correlate with recurrence of non-small cell lung cancer

JAML promotes the antitumor role of tumor-resident CD8 + T cells by facilitating their innate-like function in human lung cancer

CD57-positive CD8 + T cells define the response to anti-programmed cell death protein-1 immunotherapy in patients with advanced non-small cell lung cancer

CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor

Unveiling the influence of tumor and immune signatures on immune checkpoint therapy in advanced lung cancer

Abstract 2278: Unraveling immune dynamics of CD4+ in non-small cell lung cancer through single-cell analysis and gene expression profiling

Association of the T-cell Receptor Landscape with Survival in Non-Small Cell Lung Cancer.

Co-expression of Receptor Tyrosine Kinases and CD8 T-lymphocyte Genes is Associated with Distinct Prognoses, Immune Cell Infiltration Patterns and Immunogenicity in Cancers

Single-cell sequencing on CD8+ TILs revealed the nature of exhausted T cells recognizing neoantigen and cancer/testis antigen in non-small cell lung cancer

Tumor-intrinsic IFNα and CXCL10 are critical for immunotherapeutic efficacy by recruiting and activating T lymphocytes in tumor microenvironment

scRNA+ TCR-seq revealed dual TCR T cells antitumor response in the TME of NSCLC